Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study

S. Gerdes; D. Thaçi; C.E.M. Griffiths; P. Arenberger; J. Poetzl; G. Wuerth; M. Afonso; H. Woehling

doi:10.1111/jdv.14605

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.14605 ◽

2017 ◽

Vol 32 (3) ◽

pp. 420-427 ◽

Cited By ~ 44

Author(s):

S. Gerdes ◽

D. Thaçi ◽

C.E.M. Griffiths ◽

P. Arenberger ◽

J. Poetzl ◽

...

Keyword(s):

Phase 3 ◽

Plaque Type ◽

Originator Product

Download Full-text

27078 Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.532 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB128

Author(s):

April W. Armstrong ◽

Yan Liu ◽

Nan Li ◽

Kristian Reich ◽

Peter Foley ◽

...

Keyword(s):

Quality Of Life ◽

Treatment Effect ◽

Mediation Analysis ◽

Health Related Quality ◽

Phase 3 ◽

Plaque Type ◽

Related Quality ◽

Health Related

Download Full-text

002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis

Journal of Investigative Dermatology ◽

10.1016/j.jid.2017.07.098 ◽

2017 ◽

Vol 137 (10) ◽

pp. S193 ◽

Cited By ~ 1

Author(s):

C.E. Griffiths ◽

K. Reich ◽

D. Thaçi ◽

S. Gerdes ◽

P. Arenberger ◽

...

Keyword(s):

Plaque Type ◽

Originator Product

Download Full-text

Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis

10.26226/morressier.595a9c52d462b80296c9f7e3 ◽

2017 ◽

Author(s):

Sascha Gerdes

Keyword(s):

Plaque Type ◽

Originator Product

Download Full-text

Safety, immunogenicity, and efficacy after a single switch from reference adalimumab to the biosimilar MSB11022: Long-term results from a randomized, double-blind, 52-Week, phase 3 study in moderate-to-severe plaque-type psoriasis patients

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.10.131 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB445

Keyword(s):

Long Term Results ◽

Phase 3 ◽

Double Blind ◽

Plaque Type

Download Full-text

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

British Journal of Dermatology ◽

10.1111/bjd.15152 ◽

2017 ◽

Vol 176 (4) ◽

pp. 928-938 ◽

Cited By ~ 95

Author(s):

C.E.M. Griffiths ◽

D. Thaçi ◽

S. Gerdes ◽

P. Arenberger ◽

G. Pulka ◽

...

Keyword(s):

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Plaque Type ◽

Originator Product

Download Full-text

Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.14504 ◽

2018 ◽

Vol 45 (9) ◽

pp. 1053-1062 ◽

Cited By ~ 31

Author(s):

Mamitaro Ohtsuki ◽

Hiroshi Kubo ◽

Hitomi Morishima ◽

Ryosuke Goto ◽

Richuan Zheng ◽

...

Keyword(s):

Monoclonal Antibody ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Plaque Type ◽

Interleukin 23

Download Full-text

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(16)32127-4 ◽

2017 ◽

Vol 389 (10068) ◽

pp. 528-537 ◽

Cited By ~ 41

Author(s):

Richard B Warren ◽

Ulrich Mrowietz ◽

Ralph von Kiedrowski ◽

Johannes Niesmann ◽

Dagmar Wilsmann-Theis ◽

...

Keyword(s):

Phase 3 ◽

Double Blind ◽

Dosing Schedule ◽

Double Blind Placebo ◽

Plaque Type

Download Full-text

MILO/ENGOT-ov11: Phase-3 Study of Binimetinib versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.06.044 ◽

2020 ◽

Vol 159 ◽

pp. 22 ◽

Cited By ~ 1

Author(s):

R.N. Grisham

Keyword(s):

Fallopian Tube ◽

Low Grade ◽

Phase 3

Download Full-text

Idalopirdin bei Alzheimererkrankung: nicht besser als Plazebo

Fortschritte der Neurologie · Psychiatrie ◽

10.1055/a-0570-2372 ◽

2018 ◽

Vol 86 (08) ◽

pp. 456-457

Keyword(s):

Phase 2 ◽

Phase 3 ◽

Alzheimer Demenz

Die Blockade von Serotoninrezeptoren, insbesondere des Serotonin-Rezeptortyps 5-HT6, als Zusatztherapie in Kombination mit Cholinesterasehemmer, hat in experimentellen Versuchen sowie in einer Phase-2-Studie positive Effekte bei Demenz gezeigt. Im Rahmen eines Phase-3 Entwicklungsprogramms wurde nun die Effektivität des selektiven Serotoninrezeptor-Antagonisten Idalopirdin bei leichter bis mittelschwerer Alzheimer Demenz geprüft.

Download Full-text

Verringertes Hypoglykämierisiko mit Dapagliflozin gegenüber Glipizid als Add-on-Therapie bei Typ 2 Diabetes mellitus: 4-Jahresdaten einer Phase-3-Studie

Diabetologie und Stoffwechsel ◽

10.1055/s-0035-1549676 ◽

2015 ◽

Vol 10 (S 01) ◽

Author(s):

K Rohwedder ◽

E Johnsson ◽

SJ Parikh

Keyword(s):

Diabetes Mellitus ◽

Phase 3 ◽

Typ 2 Diabetes ◽

Typ 2 Diabetes Mellitus

Download Full-text